title: In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
abstract: BACKGROUND
  Pathogen reduction technologies (PRTs) may induce storage lesion in platelet (PLT) concentrates. To investigate this, buffy coat PLTs (BCPs) in PLT additive solution (AS; SSP+) with or without Mirasol PRT (CaridianBCT Biotechnologies) were assessed by quality control tests and four-color flow cytometry.
  
  
  METHODS
  In vitro comparison of PRT and control pooled-and-split BCPs after 2, 3, 6, 7, and 8 days of storage was made. PLT concentration, count per unit, swirl, metabolism, activation (CD62P, PAC1, CD42b/GPIb, CD63, CD40L/CD154, CD40, annexin V), and microparticle, sCD40L, and sCD62P release were evaluated.
  
  
  RESULTS
  PRT induced a minor initial PLT loss (Day 2 [mean±SD], 302×10(9) ±44×10(9) PLTs/unit vs. 325× 10(9) ±46×10(9) PLTs/unit; p<0.001) but the decline was comparable to control BCP. Swirling was comparable and declined with similar rates in PRT-treated and control BCPs during storage. PRT enhanced PLT metabolism and activation, evidenced by lower pH(22) ; increased glucose consumption and lactate production rates (p<0.01); early increases in CD62P-, PAC1-, CD63-, CD40L-, CD40-, and annexin V-positive PLTs; reduced GPIb expression; and enhanced release of PLT-derived MPs and sCD40L (all p<0.05). CD62P and PAC1 expression changed with different kinetics during storage and varying GPIb expression was displayed within the CD62P/PAC1-positive PLT subsets.
  
  
  CONCLUSIONS
  PRT treatment of BCP in AS induced a minor initial PLT loss and enhanced metabolism and PLT activation. The clinical relevance for PLT function in vivo of these findings will be investigated in a clinical trial.
authors.affiliation: Section for Transfusion Medicine, Capital Region Blood Bank, Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. sisse.ostrowski@gmail.com
authors.forename: Sisse R
authors.initials: SR
authors.lastname: Ostrowski
authors.forename: Louise
authors.initials: L
authors.lastname: Bochsen
authors.forename: José A
authors.initials: JA
authors.lastname: Salado-Jimena
authors.forename: Henrik
authors.initials: H
authors.lastname: Ullum
authors.forename: Inge
authors.initials: I
authors.lastname: Reynaerts
authors.forename: Raymond P
authors.initials: RP
authors.lastname: Goodrich
authors.forename: Pär I
authors.initials: PI
authors.lastname: Johansson
mesh_terms: D058621:Blood Buffy Coat / Q000166:cytology*; D001792:Blood Platelets / Q000166:cytology* / Q000382:microbiology / Q000528:radiation effects; D001793:Blood Preservation / Q000379:methods*; D017848:Blood-Borne Pathogens / Q000528:radiation effects; D005434:Flow Cytometry; D006801:Humans; D017319:Photosensitizing Agents / Q000737:chemistry; D012256:Riboflavin / Q000737:chemistry; D014466:Ultraviolet Rays
chemical_list: D017319:Photosensitizing Agents; D012256:Riboflavin